Annual report pursuant to Section 13 and 15(d)

Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.10.0.1
Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2016
Net sales $ 180,254 $ 163,973 $ 154,153 $ 144,613 $ 156,578 $ 144,037 $ 131,807 $ 130,581 $ 642,993 $ 563,003 $ 499,023
Operating income                 136,178 120,584 150,593
Costs recognized upon sale of acquired inventory                 (2,455) (3,037) (5,431)
Amortization of intangibles                 (47,076) (44,393) (29,395)
Corporate general, selling and administrative expenses                 (240,636) (200,443) (140,879)
Acquisition Related [Member]                      
Corporate general, selling and administrative expenses                 (6,715) (4,952) (5,007)
Operating Segments [Member]                      
Operating income                 245,376 213,386 202,617
Intersegment Eliminations [Member]                      
Net sales                 (536) (104) (125)
Segment Reconciling Items [Member]                      
Acquisition related expenses                 (24,429) (25,789) (2,761)
Restructuring costs                 (376)
Stock-based compensation                 (28,240) (14,631) (9,430)
Biotechnology [Member] | Operating Segments [Member]                      
Net sales                 421,536 364,504 317,340
Operating income                 199,100 175,163 168,613
Protein Platforms [Member] | Operating Segments [Member]                      
Net sales                 111,885 91,464 77,324
Operating income                 17,996 9,648 3,592
Diagnostics [Member] | Operating Segments [Member]                      
Net sales                 110,108 107,139 104,484
Operating income                 $ 28,280 $ 28,575 $ 30,412